Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

AUG 25, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca, Peregrine Team Up for Immuno-Oncology Study

AstraZeneca (AZN) inked a clinical trial collaboration with Peregrine to evaluate bavituximab plus durvalumab in a phase I/Ib study.

Tags: AstraZeneca, Peregrine Team Up for Immuno-Oncology Study ,  Astrazeneca Latest News

AUG 24, 2015 - Benzinga

A Must Read - Share

AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

AstraZeneca (NYSE: AZN) and Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced that they have entered into a cancer immunotherapy clinical trial collaboration.

Tags: AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial,  Astrazeneca Latest News

AUG 21, 2015 - TheStreet

A Must Read - Share

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

BOSTON (TheStreet) -- This is the "I took a vacation and stuff happened" Biotech Stock Mailbag. Manish R. emails, "You've been quite bullish on Celldex Therapeutics in the past so I was surprised when you didn't comment at all on the company's recent setback as it relates to Rintega and the lack of an [FDA] accelerated approval application. What are ...

Tags: Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio,  Astrazeneca Latest News

AUG 12, 2015 - USA Today

A Must Read - Share

AstraZeneca bolsters cancer pipeline with partnerships

Partnerships for oncology medicines could generate more than $1 billion in revenue.        

Tags: AstraZeneca bolsters cancer pipeline with partnerships,  Astrazeneca Latest News

AUG 12, 2015 - TheStreet

A Must Read - Share

Jim Cramer's Top Takeaways: WisdomTree Investments, Google, Charles River Labs

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading. WETF data by YCharts WisdomTree Investments : In an exclusive interview, Cramer sat down with Jonathan Steinberg, president and CEO at WisdomTree, ...

Tags: Jim Cramer's Top Takeaways: WisdomTree Investments, Google, Charles River Labs,  Astrazeneca Latest News